Should I buy Corteva (CTVA) stock or is it too late?

Corteva · Materials · price $82

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 64% of its targets hit on this sector (176 calls tested). It aims for $85 (+3.2 %), call made on August 19, 2026, maturing on August 19, 2027 (9 d ago).

The 6 reliable analysts $88.50+7.4 %

The 6 other firms $95+15 %

How to read it: the 6 reliable firms are not filtered by optimism — 6 aim above the price, 0 below, hence their $88.50 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Corteva

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Keybanc	83 %	+17.9 %	24	$85 +3%
Oppenheimer	100 %	+16.7 %	8	$95 +15%
RBC Capital	71 %	+15.8 %	14	$103 +25%
UBS	90 %	+14.1 %	10	$85 +3%
Morgan Stanley	78 %	+13.3 %	9	$95 +15%
Citigroup	69 %	+9.6 %	13	$86 +4%
BMO Capital	71 %	+8.1 %	7	$100 +21%
Wells Fargo	69 %	+8.0 %	13	$90 +9%

In short — Should you invest in Corteva? Is it too late, still worth it? Analysts are fairly positive (75% buy, median target $93, i.e. +13%), and the most reliable on CTVA targets even higher. But the valuation is stretched (P/E ~50). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

75% of analysts rate it a buy (Buy consensus, 12 ratings) — a sign of market conviction.
Median price target $93, i.e. +13% from the current price ($82).
The most reliable firm on CTVA, Oppenheimer (100% hit rate, 8 scored calls), targets $95 (call made on July 23, 2026, maturing on July 23, 2027) (+15%) in its most recent call, and $78 (call made on January 27, 2026, maturing on January 27, 2027) (-5%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 12 ratings, 3 are neutral.
High valuation (P/E ~50): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on CTVA

Median target $93 (+13%) · 12 ratings · Buy consensus

Strong Buy00%

Buy975%

Hold325%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Corteva now?

We won't decide for you. The facts: 75% of analysts rate it a buy, median target $93 (+13%), and Oppenheimer (most reliable on CTVA, 100%) targets $95. Weigh that against valuation (P/E ~50). This is not personalized advice.

Is it too late to invest in Corteva?

Not according to analysts: the median target ($93) is still +13% above the current price ($82) (most reliable on CTVA: Oppenheimer, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Corteva still worth investing in?

It depends on the gap between the price ($82) and its estimated value: analysts target $93 on median (+13%), with 75% buys (most reliable on CTVA: Oppenheimer, 100%). Cross-check with their real reliability on CTVA and the cautions above. Information, not advice.

What's the main risk in buying CTVA?

The consensus is not unanimous: of 12 ratings, 3 are neutral.

→ Go deeper: the full Corteva profile (consensus, analyst reliability, price target, performance).